Validated markers are needed to identify operable lung cancer patients with poor prognosis. About one-half of nonsmall-cell lung cancers (NSCLCs) carry a mutation in the p53 tumor-suppressor gene. We examined 101 NSCLC patients for surgical stage, completeness of resection, tobacco smoking, asbestos
A small-cell lung cancer genome with complex signatures of tobacco exposure
✍ Scribed by Pleasance, Erin D.; Stephens, Philip J.; O’Meara, Sarah; McBride, David J.; Meynert, Alison; Jones, David; Lin, Meng-Lay; Beare, David; Lau, King Wai; Greenman, Chris
- Book ID
- 109898585
- Publisher
- Nature Publishing Group
- Year
- 2009
- Tongue
- English
- Weight
- 1024 KB
- Volume
- 463
- Category
- Article
- ISSN
- 0028-0836
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract LINE‐1 and Alu elements are non‐LTR retrotransposons, constituting together over 30% of the human genome and they are frequently hypomethylated in human tumors. A relationship between global hypomethylation and genomic instability has been shown, however, there is little evidence to sug
Inactivation of p16(INK4a) in the Rb pathway is among the most common somatic alterations observed in nonsmall cell lung cancers (NSCLCs). While epigenetic inactivation of the p16(INK4a) gene promoter has been shown to be associated with increased tobacco carcinogen exposure, little investigation of